Arrowhead Pharmaceuticals, Inc.
Developer of RNA interference drugs that silence disease-causing genes, with an approved treatment for a rare lipid disorder and multiple drug candidates in clinical trials.
From the annual report
A. Overview The Company develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. There are approximately 20 Arrowhead discovered drug candidates in clinical trials ranging from early stage (Phase 1) to late stage (Phase 3), including both partnered and wholly-owned candidates. In addition, the Company has a robust discovery stage pipeline which is capable of generating multiple new clinical candidates each year. The Company achieved a transformational milestone with its first commercial launch in 2025, when the U.S. Food and Drug Administration ("FDA") approved REDEMPLO (plozasiran) as an adjunct to diet to reduce triglycerides (TGs) in adults with Familial Chylomicronemia Syndrome ("FCS"). REDEMPLO subsequently received marketing authorization for FCS in the European Union, Canada, Australia, China, and the United Kingdom. Additionally, Arrowhead presented results from the pivotal Phase 3 SHASTA-3 and SHASTA-4 studies of plozasiran in adults with severe hypertriglyceridemia (sHTG) during a Hot Line Late-Breaking Science session at the European Society of Cardiology (ESC) Congress 2026 in Munich, Germany. SHASTA-3 and SHASTA-4 met their primary and all prespecified secondary endpoints and demonstrated deep and durable reductions in TGs, with median reductions from baseline of 79% and 81%, respectively, at Month 12 (p 0.0001 in both studies).
Run a full DCF model with Monte Carlo simulation.